Blue Jet Health
Blue Jet Health Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
3 of 4 strong
Not discussed on this call: fundraise.
The short version
Robust order book and strong visibility for the next several quarters, especially in PI/API segment. Blue Jet Healthcare expects sustained strong revenue growth in PI/API segment for next 3-4 quarters due to secular growth and strong order book (Page 8).
From Blue Jet Health's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Robust order book and strong visibility for the next several quarters, especially in PI/API segment.
- Incremental sales of INR30 crores likely to be recognized next quarter, subject to goods in transit variances.
- 3 candidates expected to launch in FY27 in Contrast Media; ongoing pilot for high-intensity sweetener.
- 20+ high conviction NCE RFPs being tracked with potential materialization of ~20%.
- Expectation of at least 2 lateral entry programs to fructify in near to medium term with initial clinical/validation quantities.
- Capacity expansion at Vizag and Mahad projects will support growth in complex APIs and CDMO manufacturing.
- Sustainable secular growth in PI/API tied to strong prescription market and consistent order book.
- FY27 capex guidance maintained at INR400-odd crores to support growth.
- Overall confidence in medium-to-long-term growth trajectory, with diversification beyond PI/API segments.
Profitability & Margins
See what Blue Jet Health said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- **Mahad Facility:** Investment of about INR210 crores already spent, with an additional INR40 crores committed to complete this phase. It is a globally scaled manufacturing facility for contrast media intermediates, expected to commission later in 2026, enhancing supply security and vertical integration.
- **Vizag Facility:** Secured ~100 acres, planning Phase 1 investment of ~INR1,000 crores over 3 years, focusing on expanding contrast media manufacturing, multipurpose finishing blocks, flexible capacities for lateral entries, high-intensity sweetener production, and intermediate clusters. Consent to establish obtained and preconstruction activities underway.
- **R&D Center:** New facility with focus on peptides, GLP-1 intermediates, biocatalysts, continuous manufacturing, flow synthesis, and complex synthetic pathways. First phase expected operational by August 2026, strengthening CDMO capabilities and accelerating customer responsiveness.
- **FY27 Capex Guidance:** Around INR400 crores planned, consistent with prior guidance.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Blue Jet Health said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Blue Jet Healthcare Limited has a robust order book with good visibility for the next several quarters.
- The company is tracking approximately 20 high-conviction RFPs (Request for Proposals), mostly in the chronic therapy space, with the potential for diversification beyond the current portfolio.
- Of these 20 high-conviction opportunities, around 20% are expected to materialize into business.
- New opportunities include 4 programs progressing well with innovator companies, alongside existing commercial orders.
- The cardiovascular (PI/API) segment has strong order books and steady production visibility for at least the next 3-4 quarters.
- Validation or trial quantities for new molecules are factored in, with bulk commercial volumes expected later.
- The company expects 2 lateral entry molecules to fructify soon, with more definitive updates to come in future quarters.
Blue Jet Health — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹235 Cr, net profit ₹64 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Blue Jet Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Novartis India Ltd (Q1 FY27)
Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of…
- IOL Chemicals & Pharmaceuticals Ltd (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab Ltd (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharmaceuticals Ltd (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
Frequently Asked Questions
What were Blue Jet Health Q1 FY27 results?
Robust order book and strong visibility for the next several quarters, especially in PI/API segment. Blue Jet Healthcare expects sustained strong revenue growth in PI/API segment for next 3-4 quarters due to secular growth and strong order book (Page 8).
What is Blue Jet Health share price analysis?
Blue Jet Health currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 48.0 with a market cap of ₹11,284 Cr. Investors should review the full earnings analysis for detailed insights.
Is Blue Jet Health planning capital expenditure?
Mahad Facility:** Investment of about INR210 crores already spent, with an additional INR40 crores committed to complete this phase.
Keep Blue Jet Health on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.